journal
MENU ▼
Read by QxMD icon Read
search

Melanoma Research

journal
https://www.readbyqxmd.com/read/29768284/predictive-value-of-excision-repair-cross-complementing-group-2-gene-lys751gln-and-asp312asn-polymorphisms-in-melanoma-risk
#1
Xue Zhou, Yong Zeng, Huayong Jiang, Limei Xia, Chuan Liu
Epidemiological studies have assessed the association between excision repair cross-complementing group 2 (ERCC2) Lys751Gln and Asp312Asn polymorphisms and melanoma risk with conflicting results. Relevant articles were searched from PubMed, Embase, and Web of Science with a time limit of 3 September 2016. Pooled odds ratio (OR) with 95% confidence interval (CI) was used to assess the strength of the association. We performed this meta-analysis with 12 studies including 6157 cases and 8873 controls for Lys751Gln and nine studies including 5037 cases and 7542 controls for Asp312Asn polymorphism...
May 15, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29762190/epidemiological-trends-in-the-diagnosis-of-melanoma-in-a-southern-european-population-analysis-of-a-large-database-from-a-tertiary-referral-center
#2
Dimosthenis Tsoutsos, Stefanos Papadopoulos, George Kehagias, Aristea Mara, Eugenia Kyriopoulou, Athanasios Karonidis, Konstantinos Spiliopoulos, Efstathios Mpalitsaris, George Karapiperis, Peter Panayotou, Eugenia Papaliodi, Theodosia Choreftaki, George Papaxoinis, Olga Benopoulou, John Ioannovich, Helen Gogas
The aim of this study was to present the epidemiological, clinicopathological, and treatment characteristics of patients diagnosed and treated in a tertiary referral center and to analyze independent factors associated with these characteristics. In this cohort study, epidemiological, clinicopathological, and treatment characteristics of 1461 consecutive melanoma patients diagnosed and treated in a tertiary referral center in 1987-2015 were prospectively collected in a registry. All patients underwent resection of their melanoma lesion...
May 14, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29750753/immune-checkpoint-inhibitor-anti-ctla-4-anti-pd-1-therapy-alone-versus-immune-checkpoint-inhibitor-anti-ctla-4-anti-pd-1-therapy-in-combination-with-anti-rankl-denosumuab-in-malignant-melanoma-a-retrospective-analysis-at-a-tertiary-care-center
#3
Muhammad Z Afzal, Keisuke Shirai
Denosumab is a monoclonal antibody against RANK ligand with a role in the prevention of skeletal-related events and is also known to possess antitumor properties. In this retrospective review, we aim to evaluate the synergist effect of a combination therapy with immune checkpoint inhibitors and denosumab in malignant melanoma patients. Patients of 18 years of age or older with a diagnosis of malignant melanoma who have received immune checkpoint inhibitors and denosumab between June 2015 and May 2017 were divided into two cohorts: cohort A (immune checkpoint inhibitors only) and cohort B (immune checkpoint inhibitors and denosumab)...
May 10, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29750752/serum-exosomal-micrornas-as-potent-circulating-biomarkers-for-melanoma
#4
Li Tengda, Long Shuping, Gu Mingli, Guo Jie, Liu Yun, Zhang Weiwei, Deng Anmei
Exosomes are small homogenous membrane vesicles that derive from the exocytosis process of cells and can contain DNA, microRNAs (miRNAs), and/or proteins. Characterization of the content profile of exosomes may reflect the state of the cells that release them, and this could be predictive of disease. In this study, to explore the potential biomarkers for melanoma, we isolated serous exosomes from 30 patients with melanoma and 30 healthy individuals using the ultracentrifugation method. Five miRNAs were subsequently detected in each sample by quantitative reverse transcription-PCR: miRNA-532-5p, miRNA-106b, miRNA-200c, miRNA-199a-5p, and miRNA-210...
May 10, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29750751/the-impact-of-patient-characteristics-and-disease-specific-factors-on-first-line-treatment-decisions-for-braf-mutated-melanoma-results-from-a-european-expert-panel-study
#5
Paolo A Ascierto, Lars Bastholt, Pier F Ferrucci, Johan Hansson, Iván Márquez Rodas, Miranda Payne, Caroline Robert, Luc Thomas, Jochen S Utikal, Pascal Wolter, Amber Kudlac, Harriet Tuson, Jan McKendrick
Treatment decisions for advanced melanoma are increasingly complex and guidelines provide limited advice on how to choose between immunotherapy and targeted therapy for first-line treatment. A Delphi study was carried out to understand which patient characteristics and disease-related factors inform clinicians' choices of first-line treatment for BRAF-mutated melanoma. Twelve European melanoma specialists experienced in using immunotherapies and targeted agents participated in a double-blind two-phase Delphi study...
May 10, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29750750/malignant-melanoma-clinically-mimicking-pyogenic-granuloma-comparison-of-clinical-evaluation-and-histopathology
#6
Michael Moshe, Assi Levi, Dean Ad-El, Dan Ben-Amitai, Daniel Mimouni, Elena Didkovsky, Meora Feinmesser, Moshe Lapidoth
Amelanotic melanomas (AMMs) account for a small proportion of all melanomas. They pose a risk of delayed diagnosis and, consequently, poor prognosis. AMMs may atypically present as a pyogenic granuloma-like lesion. This study sought to investigate the prevalence and clinical and histological features of AMM masquerading as pyogenic granuloma. The database of a tertiary medical center was screened for all patients pathologically diagnosed with melanoma in 2005-2016. Those with a suspected primary (i.e. pre-excision) clinical diagnosis of pyogenic granuloma were identified, and their demographic, clinical, histologic, and outcome data were collected from the medical files...
May 10, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29750749/vemurafenib-in-braf-mutant-metastatic-melanoma-patients-in-real-world-clinical-practice-prognostic-factors-associated-with-clinical-outcomes
#7
Maartje G Schouwenburg, Anouk Jochems, Brenda Leeneman, Margreet G Franken, Alfons J M van den Eertwegh, John B A G Haanen, Michiel C T van Zeijl, Maureen J Aarts, Alexander C J van Akkooi, Franchette W P J van den Berkmortel, Willeke A M Blokx, Jan Willem B de Groot, Geke A P Hospers, Ellen Kapiteijn, Rutger H Koornstra, Wim H Kruit, Marieke W J Louwman, Djura Piersma, Rozemarijn S van Rijn, Karijn P M Suijkerbuijk, Albert J Ten Tije, Gerard Vreugdenhil, Michel W J M Wouters, Jacobus J M van der Hoeven
The aim of this population-based study was to identify the factors associated with clinical outcomes in vemurafenib-treated patients and to evaluate outcomes across subgroups of patients with different risk profiles. Data were retrieved from the Dutch Melanoma Treatment Registry. Time to next treatment (TTNT) and overall survival (OS) of all metastatic melanoma patients who received vemurafenib between 2012 and 2015 were assessed using Kaplan-Meier estimates. A risk score was developed on the basis of all prognostic factors associated with TTNT and OS derived from multivariable Cox regression analyses...
May 10, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29746316/the-clinical-significance-of-kit-mutations-in-melanoma-a-meta-analysis
#8
Hui Z Gong, He Y Zheng, Jun Li
This study aimed to evaluate the association of KIT mutations with clinicopathologic features of melanomas using a meta-analysis and to identify differences between Asian and White populations using subgroup analyses. We selected 32 studies from the literature including 5224 patients. The pooled data were combined, and odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Heterogeneity and publication bias were also determined. KIT mutations were reported in 497 (9.5%) of 5224 patients with melanomas, and were associated significantly with age, clinical melanoma subtype, anatomic location, and chronic sun-damage (CSD), but not with sex, histological type, Breslow thickness, ulceration, mitotic rate, or tumor stage...
May 9, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29683859/correlation-with-lymphocyte-infiltration-but-lack-of-prognostic-significance-of-meca-79-positive-high-endothelial-venules-in-primary-malignant-melanoma
#9
Tímea Sebestyén, Anita Mohos, Gabriella Liszkay, Beáta Somlai, István Gaudi, Andrea Ladányi
High endothelial venules (HEVs) are specialized vessels in lymphoid organs, supporting lymphocyte trafficking from the blood. As the presence of these vessels was described recently in tumors, it was proposed that they could facilitate the development of antitumor immune response, resulting in improved prognosis. The aim of our study was to analyze the correlation of the density of HEVs with that of the different immune cell types as well as with the clinicopathologic parameters and the disease outcomes in patients with cutaneous melanoma...
April 20, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29634635/clinicopathological-significance-of-tumor-infiltrating-lymphocytes-and-programmed-death-1-expression-in-cutaneous-melanoma-a-comparative-study-on-clinical-subtypes
#10
Woo J Lee, Ye J Lee, Ho J Shin, Chong H Won, Sung E Chang, Jee H Choi, Mi W Lee
Interactions between immune cells and tumor cells play an important role in tumor progression. We evaluated patterns of tumor-infiltrating lymphocytes (TILs) and programmed death-1 (PD-1) expression in acral and nonacral cutaneous melanoma, and determined their effects on clinicopathological characteristics and biologic responses. We identified 122 cases of cutaneous melanoma, of which 39 were cases of non-nail unit acral melanoma (NNUAM), 35 were cases of nail unit melanoma (NUM), and 48 were cases of nonacral melanoma...
April 9, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29634634/immune-privilege-failure-of-immunotherapy-in-controlling-metastatic-cutaneous-melanoma-to-the-eye
#11
David I T Sia, Caroline Thaung, Ciara O'Hanlon-Brown, Victoria M L Cohen, Mandeep S Sagoo
This report concerns a 49-year-old female with cutaneous malignant melanoma and systemic metastases. These resolved following combination immunotherapy with ipilimumab and nivolumab. She subsequently experienced unilateral floaters, an increase in iris pigmentation and pigmentary glaucoma. The eye progressively lost vision and became painful due to iris neovascularization. The clinical diagnosis was of cutaneous melanoma metastatic to the vitreous, ciliary body and iris. Enucleation was performed for symptom control, with histopathology confirming the clinical diagnosis...
April 9, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29596115/sensitization-of-recombinant-human-tumor-necrosis-factor-related-apoptosis-inducing-ligand-resistant-malignant-melanomas-by-quercetin
#12
Katherine A Turner, Jasmine M Manouchehri, Michael Kalafatis
Malignant melanoma is the most commonly diagnosed skin cancer associated with a high rate of metastasis. Low-stage melanoma is easily treated, but metastatic malignant melanoma is an extremely treatment-resistant malignancy with low survival rates. The application of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) for the treatment of metastatic malignant melanoma holds considerable promise because of its selective proapoptotic activity towards cancer cells and not nontransformed cells...
March 28, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29595571/targeted-ultrasound-and-fine-needle-aspiration-cytology-for-sentinel-node-diagnostics-in-early-stage-melanoma-a-validation-study
#13
Niels K Ternov, Trine-Lise Lambine, Anne L H Wagenblast, Erik Clasen-Linde, Peter S Oturai, Helle Klyver, Kristina R Nielsen, Michael B Nielsen, Krzysztof T Drzewiecki, Annette H Chakera
Ultrasound-guided fine-needle aspiration cytology (US-FNAC) is used to evaluate the involvement of lymph nodes in various malignant diseases. Its value in detecting sentinel lymph node (SN) metastasis preoperatively in melanoma patients is controversial and is the subject of this study. In this prospective validation study, 91 consecutive patients with melanoma clinical stage I (n=64) and II (n=27) were examined with US-FNAC before SN biopsy from 2012 to 2014 at a tertiary center. All patients underwent lymphoscintigraphy before the US-FNAC...
March 27, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29570170/fatty-acid-receptor-gpr120-a-novel-marker-for-human-melanoma
#14
Johannes Kleemann, Igor Hrgovic, Jan Ter-Nedden, Pia Kleimann, Katja Steinhorst, Katja Härle, Jutta Müller, Roland Kaufmann, Markus Meissner, Stefan Kippenberger
The correlation between ultraviolet radiation of the skin and melanoma incidence in humans is well established. Interestingly, epidemiologic data suggest also a correlation to an increased BMI pointing to metabolic trigger factors in melanoma pathogenesis. To substantiate this connection, we studied the expression of G-protein-coupled receptor 120 (GPR120), a receptor sensitive to unsaturated long-chain free fatty acids in melanoma tissues. One-hundred fourteen tissue sections histologically confirmed as nevi (n=32), primary melanoma (n=39), and melanoma metastasis (n=43) were immunohistochemically stained against GPR120...
March 21, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29570169/telomerase-reverse-transcriptase-promoter-mutations-and-solar-elastosis-in-cutaneous-melanoma
#15
Johanne Lade-Keller, Sakineh Yuusufi, Rikke Riber-Hansen, Torben Steiniche, Magnus Stougaard
The aims of this study were to assess the prognostic potential of solar elastosis grading and telomerase reverse transcriptase (TERT) promoter mutations (TERTp) in melanoma and to evaluate whether an association between solar elastosis and TERTp exists. Solar elastosis in the dermis was evaluated in hematoxylin and eosin-stained whole slides from 486 malignant melanomas. Pyrosequencing was used to detect TERTp in 189 samples. There was no association between solar elastosis and TERTp (P=0.3). Severe elastosis was associated with older age (P<0...
March 21, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29561296/potential-clinical-and-immunotherapeutic-utility-of-talimogene-laherparepvec-for-patients-with-melanoma-after-disease-progression-on-immune-checkpoint-inhibitors-and-braf-inhibitors
#16
Jason Chesney, Yoannis Imbert-Fernandez, Sucheta Telang, Mary Baum, Smita Ranjan, Mostafa Fraig, Nicolas Batty
Talimogene laherparepvec is a genetically modified herpes simplex virus type 1-based oncolytic immunotherapy for the local treatment of unresectable subcutaneous and nodal tumors in patients with melanoma recurrent after initial surgery. We report on two patients with melanoma who, after progression on numerous systemic therapies, derived clinical benefit from talimogene laherparepvec in an expanded-access protocol (ClinicalTrials.gov, NCT02147951). Intralesional talimogene laherparepvec (day 1, ≤4 ml 10 PFU/ml; after 3 weeks, ≤4 ml 10 PFU/ml every 2 weeks) was administered until complete response, no injectable tumors, progressive disease, or intolerance occurred...
March 21, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29553967/traf3-interacting-protein-3-a-new-oncotarget-promotes-tumor-growth-in-melanoma
#17
Patrick Nasarre, Ingrid V Bonilla, John S Metcalf, Eleanor G Hilliard, Nancy Klauber-DeMore
TRAF3-interacting protein 3 (TRAF3IP3) is expressed in the immune system and participates in cell maturation, tissue development, and immune response. In a previous study, we reported that TRAF3IP3 levels were substantially increased in the vasculature of breast cancer tissues, suggesting a proangiogenic role. In this study, we investigated TRAF3IP3 tumorigenic function. TRAF3IP3 protein was present in several cancer cell lines, with highest levels in melanoma. In addition, tumor microarray analysis on 23 primary melanoma and nine positive lymph nodes revealed that 70% of human primary melanoma and 66% of lymph node metastases were positive for TRAF3IP3...
March 16, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29543704/three-antigen-loading-methods-in-dendritic-cell-vaccines-for-metastatic-melanoma
#18
Larisa J Geskin, James J Damiano, Christina C Patrone, Lisa H Butterfield, John M Kirkwood, Louis D Falo
In the current era of checkpoint inhibitors, some patients with metastatic melanoma have shown a significant improvement in survival. However, optimization of immunotherapy is an ongoing effort. Monocyte-derived dendritic cell (MODC) vaccines have been shown in clinical trials to be safe and capable of inducing tumor-specific immunity as well as occasional objective clinical responses. Here, we conducted a three-arm pilot clinical study in 15 patients with metastatic melanoma to evaluate three types of MODC vaccines, differing only by strategies of tumor antigen delivery...
March 14, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29543703/cdkn2a-germline-alterations-in-melanoma-patients-with-personal-or-familial-history-of-pancreatic-cancer
#19
Blanca De Unamuno, Zaida García-Casado, José Bañuls, Celia Requena, José Antonio Lopez-Guerrero, Eduardo Nagore
CDKN2A germline mutations increase the risk of melanoma development and are present in 20 and 10% of familial and multiple melanoma cases, respectively. Pancreatic cancer has been associated with CDKN2A in some populations and, accordingly, its presence in first-degree or second-degree relatives of a melanoma patient is considered as a criterion for genetic testing. In this study, we show that in an area with low melanoma incidence, CDKN2A germline mutations in patients with melanoma and personal or family history of pancreatic cancer are mainly present in the setting of familial or multiple melanoma cases...
March 14, 2018: Melanoma Research
https://www.readbyqxmd.com/read/29538091/lymphoid-aggregates-in-desmoplastic-melanoma-have-features-of-tertiary-lymphoid-structures
#20
Anne M Stowman, Alexandra W Hickman, Ileana S Mauldin, Adela Mahmutovic, Alejandro A Gru, Craig L Slingluff
Desmoplastic melanomas (DM) have unique and challenging clinical presentations and histomorphology. A characteristic feature is the presence of scattered lymphoid aggregates. However, the nature of these aggregates is not defined. We hypothesized that they may be tertiary lymphoid structures (TLS), and may be associated with programmed death ligand 1 (PD-L1) expression. We searched our tissue database for 'pure' DMs and for scars as control tissues, collected clinical information, and reviewed H&E histology...
March 13, 2018: Melanoma Research
journal
journal
30785
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"